- TRADE NAME: Rydapt (Novartis)
- INDICATIONS: Aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast cell leukemia; acute myeloid leukemia (FLT3 mutation-positive) in combination with cytarabine and daunorubicin induction and cytarabine consolidation
- CLASS: Multikinase inhibitor
- HALF-LIFE: 21 hours
- FDA APPROVAL DATE: 04/28/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Boceprevir, Carbamazepine, Clarithromycin, Cobicistat, Conivaptan, Danoprevir, Diltiazem, Elvitegravir, Enzalutamide, Grapefruit Juice, Idelalisib, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Mitotane, Nefazodone, Nelfinavir, Ombitasvir/Paritaprevir/Ritonavir, Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir, Phenytoin, Posaconazole, Rifampin, Ritonavir, Saquinavir, St John's Wort, Stong CYP3A inducers and inhibitors, Tipranavir, Troleandomycin, Voriconazole - PREGNANCY: May cause fetal toxicity based on findings in animal studies
Please login to view the rest of this drug profile.
Page last updated 06/24/2024
